CA2712619C - Composes antagonistes du calcium de type dihydropyridine, procedes de preparation et utilisations medicales de ces composes - Google Patents

Composes antagonistes du calcium de type dihydropyridine, procedes de preparation et utilisations medicales de ces composes Download PDF

Info

Publication number
CA2712619C
CA2712619C CA2712619A CA2712619A CA2712619C CA 2712619 C CA2712619 C CA 2712619C CA 2712619 A CA2712619 A CA 2712619A CA 2712619 A CA2712619 A CA 2712619A CA 2712619 C CA2712619 C CA 2712619C
Authority
CA
Canada
Prior art keywords
nitrophenyl
group
dihydro
piperazinyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2712619A
Other languages
English (en)
Other versions
CA2712619A1 (fr
Inventor
Guo-Hua Chen
Li Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosunter Pharmaceutical Co
Original Assignee
Cosunter Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosunter Pharmaceutical Co filed Critical Cosunter Pharmaceutical Co
Publication of CA2712619A1 publication Critical patent/CA2712619A1/fr
Application granted granted Critical
Publication of CA2712619C publication Critical patent/CA2712619C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne des composés antagonistes du calcium de type dihydropyridine, des procédés de préparation et des utilisations médicales de ces composés. L'invention concerne en particulier des procédés de préparation des composés représentés par la formule (I) et (II) et des sels pharmaceutiquement acceptables de ceux-ci et, leurs utilisations dans le traitement de maladies cardio-vasculaires. Dans ces formules, R1 représente un cycle aromatique ou un groupe aralkyle, hétérocyclique, substitué ou non, les substituants pouvant être C1-C4alkyle, C1-C4alkoxyle, halogène, cyano, trifluorométhyle, trifluorométhoxyle, méthylthio, nitro, amino ou hydroxyle; R2 représente C1-C8alkyle; R3 et R4 peuvent être semblables ou différents, et chacun indépendamment représente hydrogène, halogène, cyano, trifluorométhyle, trifluorométhoxyle, méthylthio, nitro, amino ou C1-C4alkyle, C1-C4alkoxyle, C1-C4alkényle, C1-C4alkynyle; R5 et R6 sont semblables ou différents et chacun représente C1-C4alkyle; X représente O, S ou une liaison simple, m=0-6, n=1-6, et m et n peuvent être semblables ou différents.
CA2712619A 2008-01-21 2009-01-05 Composes antagonistes du calcium de type dihydropyridine, procedes de preparation et utilisations medicales de ces composes Active CA2712619C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200810018711.6 2008-01-21
CNA2008100187116A CN101215258A (zh) 2008-01-21 2008-01-21 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途
PCT/CN2009/070031 WO2009092301A1 (fr) 2008-01-21 2009-01-05 Composés antagonistes du calcium de type dihydropyridine, procédés de préparation et utilisations médicales de ces composés

Publications (2)

Publication Number Publication Date
CA2712619A1 CA2712619A1 (fr) 2009-07-30
CA2712619C true CA2712619C (fr) 2013-03-26

Family

ID=39621777

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2712619A Active CA2712619C (fr) 2008-01-21 2009-01-05 Composes antagonistes du calcium de type dihydropyridine, procedes de preparation et utilisations medicales de ces composes

Country Status (7)

Country Link
US (1) US8163907B2 (fr)
EP (1) EP2251337B1 (fr)
JP (1) JP2011509948A (fr)
KR (1) KR101215785B1 (fr)
CN (2) CN101215258A (fr)
CA (1) CA2712619C (fr)
WO (1) WO2009092301A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101215258A (zh) * 2008-01-21 2008-07-09 中国药科大学 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途
CN102372692B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 二氢吡啶衍生物
US8718389B2 (en) 2011-04-13 2014-05-06 Huawei Technologies Co., Ltd. Image encoding and decoding methods and related devices
AU2014225550C1 (en) 2013-03-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
WO2019094856A1 (fr) 2017-11-13 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs atypiques de transporteurs de monoamine ; leur procédé de production et d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094159B1 (fr) * 1982-05-10 1990-03-14 Takeda Chemical Industries, Ltd. Dérivés de la dihydropyridine, leur préparation et leur application
DE3377352D1 (en) * 1982-06-03 1988-08-18 Pierrel Spa Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them
JPS6048970A (ja) * 1983-08-25 1985-03-16 Takeda Chem Ind Ltd ジヒドロピリジン誘導体
US4755512A (en) * 1984-04-11 1988-07-05 Bristol-Myers Company Pharmaceutically useful dihydropyridinyldicarboxylate amides and esters incorporating arylpiperazinylalkyl moities
GB8503424D0 (en) * 1985-02-11 1985-03-13 Ici Plc Heterocyclic derivatives
JPS61194069A (ja) * 1985-02-25 1986-08-28 Kyoto Yakuhin Kogyo Kk １，４−ジヒドロピリジン誘導体
JPS6391366A (ja) * 1986-10-03 1988-04-22 Kyoto Yakuhin Kogyo Kk １，４−ジヒドロピリジン誘導体
US4994461A (en) * 1987-03-27 1991-02-19 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridine enantiomers
WO1991009847A1 (fr) * 1989-12-29 1991-07-11 Kaken Pharmaceutical Co., Ltd. Derive d'ethynylphenyle, production de ce derive et medicament de traitement des maladies des organes du systeme circulatoire contenant ce derive comme ingredient actif
JPH04244081A (ja) * 1991-01-31 1992-09-01 Kaken Pharmaceut Co Ltd １，４−ジヒドロピリジン誘導体およびそれを有効成分とするアレルギー性または炎症性疾患治療剤
JPH08502038A (ja) * 1992-07-28 1996-03-05 藤沢薬品工業株式会社 抗高血圧作用を有する１，４−ジヒドロピリジン誘導体およびその製造方法
US5559004A (en) * 1994-07-12 1996-09-24 The Regents Of The University Of California Methods for screening compounds to determine calcium leak channel inhibition activity
WO2004033444A1 (fr) * 2002-10-07 2004-04-22 Artesian Therapeutics, Inc. Composes de dihydropyridine presentant a la fois la capacite de bloquer des canaux calciques de type l et la capacite d'inhiber l'activite de type 3 de la phosphodiesterase
CN101215258A (zh) * 2008-01-21 2008-07-09 中国药科大学 二氢吡啶类钙拮抗剂化合物及其制备方法与医药用途

Also Published As

Publication number Publication date
US8163907B2 (en) 2012-04-24
CA2712619A1 (fr) 2009-07-30
CN101215258A (zh) 2008-07-09
US20110201811A1 (en) 2011-08-18
KR101215785B1 (ko) 2012-12-26
WO2009092301A1 (fr) 2009-07-30
EP2251337B1 (fr) 2013-11-20
CN101525314A (zh) 2009-09-09
EP2251337A1 (fr) 2010-11-17
JP2011509948A (ja) 2011-03-31
CN101525314B (zh) 2012-01-04
KR20100105781A (ko) 2010-09-29
EP2251337A4 (fr) 2011-03-30

Similar Documents

Publication Publication Date Title
CA2712619C (fr) Composes antagonistes du calcium de type dihydropyridine, procedes de preparation et utilisations medicales de ces composes
US6391881B2 (en) Thiourea derivatives of dihydropyridine NPY antagonists
TWI226240B (en) Piperazine compound
CA2174969C (fr) Dihydropyridines a activite courte
CN113214139B (zh) 哌啶酰胺类衍生物及其制备方法、其药物组合物、其单晶培养方法及其应用
IE850898L (en) Dihydropyridinyldicarboxylate amides.
JP2005504045A (ja) 塩酸レルカニジピンの新規な原形および結晶性形状
HU212133B (en) Therapeutic agents
OGAWA et al. Synthesis and antihypertensive activities of new 1, 4-dihydropyridine derivatives containing a nitrooxy moiety at the 3-ester position
US4937242A (en) 1,4-dihydropyridine derivatives and pharmaceutical composition thereof
NO164593B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbamat- eller urea-derivater.
RU2456267C2 (ru) Соль алискирена и оротовой кислоты
EP0247345A2 (fr) 1,4-Dihydropyridine-3,5-dicarboxylates incorporant une partie alkylèneaminoalkylène contenant un hétéroatome
ES2397570T3 (es) Un procedimiento para la producción de la forma V de HCI de lercanidipina
JP4897217B2 (ja) カルシウムチャンネル遮断薬
CA1205471A (fr) Dihydropyridines
JP4559732B2 (ja) カルシウムチャンネル遮断剤としての１，４−ジヒドロピリジン化合物
JPH0155268B2 (fr)
JPS62161758A (ja) ジヒドロピリジン誘導体、その製法、これを含有する動脈血管収縮抑制剤及び脳内カルシウムイオン蓄積妨止剤
MXPA01000637A (es) Derivados de arilpiperazina utiles como bloqueadores uroselectivos de alfa 1-adrenoceptor.
SE442298B (sv) 2,6-dimetyl-4-(2,3-diklorfenyl)-1,4-dihydropyridin-3,5-dikarboxylsyra-3-metylester-5-etylester i optisk aktiv form
Belge et al. Synthesis and preliminary pharmacological screening of 4-aryl substituted-3, 4-dihydropyrimidin-2 (1H) one/thione derivatives as calcium channel blockers
Hadizadeh et al. Synthesis and calcium channel antagonist activity of 2-dimethylamino/4-benzylimidazolyl substituted dihydropyridines
JPH05230023A (ja) １，４−ジヒドロピリジン誘導体、その製法と用途
LV14036B (lv) Trīs komponentu metode ftalimidoamlodipīna iegūšanai jonu šķidrumu promotētās reakcijās

Legal Events

Date Code Title Description
EEER Examination request